分离在氯胺酮抗抑郁作用中的作用。
The role of dissociation in ketamine's antidepressant effects.
机构信息
Section on the Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, 20892, USA.
出版信息
Nat Commun. 2020 Dec 22;11(1):6431. doi: 10.1038/s41467-020-20190-4.
Abstract
Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. Ketamine also has short term dissociative effects, in which individuals report altered consciousness and perceptions of themselves and their environment. However, whether ketamine's dissociative side effects are necessary for its antidepressant effects remains unclear. This perspective examines the relationship between dissociative effects and acute and longer-lasting antidepressant response to ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists. Presently, the literature does not support the conclusion that dissociation is necessary for antidepressant response to ketamine. However, further work is needed to explore the relationship between dissociation and antidepressant response at the molecular, biomarker, and psychological levels.
摘要
氯胺酮能立即产生抗抑郁效果，激发了对下一代治疗方法的研究。氯胺酮也有短期的分离效应，个体报告意识改变和对自己和环境的感知改变。然而，氯胺酮的分离副作用是否对其抗抑郁效果是必要的尚不清楚。本观点探讨了分离作用与氯胺酮和其他 N-甲基-D-天冬氨酸（NMDA）受体拮抗剂的急性和更持久的抗抑郁反应之间的关系。目前，文献并不支持分离是对氯胺酮抗抑郁反应所必需的结论。然而，需要进一步的工作来探索分离与分子、生物标志物和心理水平抗抑郁反应之间的关系。
相似文献
1
The role of dissociation in ketamine's antidepressant effects.分离在氯胺酮抗抑郁作用中的作用。
Nat Commun. 2020 Dec 22;11(1):6431. doi: 10.1038/s41467-020-20190-4.
2
Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.氯胺酮在单相抑郁症中的抗抑郁作用与拟精神病效应的关系。
Neuro Endocrinol Lett. 2013;34(4):287-93.
3
Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.5-羟色胺能信号系统在氯胺酮抗抑郁作用中的潜在作用：一项批判性评价。
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:27-38. doi: 10.1016/j.pnpbp.2016.05.007. Epub 2016 Jun 2.
4
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.分离特征可预测难治性抑郁症患者对氯胺酮抗抑郁治疗的反应。
J Affect Disord. 2018 May;232:310-315. doi: 10.1016/j.jad.2018.02.049. Epub 2018 Feb 17.
5
Ketamine for depression.氯胺酮治疗抑郁症。
Int Rev Psychiatry. 2021 May;33(3):207-228. doi: 10.1080/09540261.2020.1854194. Epub 2021 Feb 11.
6
Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.氯胺酮的抗抑郁作用以及AMPA谷氨酸受体的作用和NMDA受体拮抗作用之外的其他机制。
J Psychiatry Neurosci. 2017 Jun;42(4):222-229. doi: 10.1503/jpn.160175.
7
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.氯胺酮和其他 NMDA 拮抗剂：抑郁症的早期临床试验和可能的机制。
Am J Psychiatry. 2015 Oct;172(10):950-66. doi: 10.1176/appi.ajp.2015.15040465.
8
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.氯胺酮快速起效的抗抑郁作用机制是什么？对大量惊人可能性的简要概述。
J Clin Pharm Ther. 2017 Apr;42(2):147-154. doi: 10.1111/jcpt.12497. Epub 2017 Jan 22.
9
Ketamine: The final frontier or another depressing end?氯胺酮：是最终的前沿领域还是又一个令人沮丧的结局？
Behav Brain Res. 2020 Apr 6;383:112508. doi: 10.1016/j.bbr.2020.112508. Epub 2020 Feb 1.
10
Mechanisms of ketamine action as an antidepressant.氯胺酮作为抗抑郁药的作用机制。
Mol Psychiatry. 2018 Apr;23(4):801-811. doi: 10.1038/mp.2017.255. Epub 2018 Mar 13.
引用本文的文献
1
Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.小胶质细胞源性脑源性神经营养因子通过皮质-伏隔核通路调节阿氯胺酮的抗抑郁样作用。
Sci Adv. 2025 Jul 11;11(28):eadv5986. doi: 10.1126/sciadv.adv5986. Epub 2025 Jul 9.
2
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteers.一项随机、双盲、安慰剂对照的1期研究，旨在调查速释口服氯胺酮胶囊在健康志愿者中的安全性、耐受性、药代动力学和药效学。
J Psychopharmacol. 2025 Jun;39(6):545-558. doi: 10.1177/02698811251340925. Epub 2025 Jun 20.
3
The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.创伤后应激障碍与首次使用艾司氯胺酮治疗难治性抑郁症时解离症状的模式有所不同。
J Affect Disord. 2025 Jun 12;389:119632. doi: 10.1016/j.jad.2025.119632.
4
Pharmacological inhibition of PSPH reduces serine levels and epileptic seizures.PSPH的药理学抑制作用可降低丝氨酸水平并减少癫痫发作。
Nat Chem Biol. 2025 Jun 2. doi: 10.1038/s41589-025-01920-5.
5
S-ketamine Alleviates Neuroinflammation and Attenuates Lipopolysaccharide-Induced Depression Via Targeting SIRT2.S-氯胺酮通过靶向SIRT2减轻神经炎症并缓解脂多糖诱导的抑郁。
Adv Sci (Weinh). 2025 Jun;12(23):e2416481. doi: 10.1002/advs.202416481. Epub 2025 Apr 2.
6
A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.食品药品监督管理局的药物研发进程及加利福尼亚州关于药用致幻剂的拟议立法综述。
Perm J. 2025 Mar 14;29(1):89-101. doi: 10.7812/TPP/24.171. Epub 2025 Feb 21.
7
Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review.2020年以来氯胺酮及其对映体快速抗自杀意念作用的临床试验：一项系统评价
Transl Psychiatry. 2025 Feb 6;15(1):44. doi: 10.1038/s41398-025-03255-0.
8
Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.S-氯胺酮用于改良根治性乳房切除术乳腺癌患者疼痛管理的疗效和安全性：一项随机对照试验的荟萃分析
Clin Transl Oncol. 2025 Feb 5. doi: 10.1007/s12094-025-03847-8.
9
Sleep-administered ketamine/psychedelics: A streamlined strategy to address two challenges in research on ketamine and psychedelics.睡眠状态下给予氯胺酮/致幻剂：应对氯胺酮和致幻剂研究中两大挑战的简化策略。
Eur Psychiatry. 2025 Feb 5;68(1):e29. doi: 10.1192/j.eurpsy.2025.14.
10
Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.探索迷幻药：从神经回路到治疗应用
Pharmaceuticals (Basel). 2025 Jan 19;18(1):130. doi: 10.3390/ph18010130.
本文引用的文献
1
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.氯胺酮和血清素能致幻剂：快速作用抗抑郁药作用的共同机制。
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):8-21. doi: 10.1093/ijnp/pyaa087.
2
Deep posteromedial cortical rhythm in dissociation.分离状态下的深部后内侧皮质节律。
Nature. 2020 Oct;586(7827):87-94. doi: 10.1038/s41586-020-2731-9. Epub 2020 Sep 16.
3
Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.“漂浮”能否预测氯胺酮治疗的反应？来自三项针对治疗抵抗性抑郁症个体的随机试验的数据。
J Psychiatr Res. 2020 Nov;130:280-285. doi: 10.1016/j.jpsychires.2020.06.012. Epub 2020 Jul 30.
4
The role of eEF2 kinase in the rapid antidepressant actions of ketamine.真核生物延伸因子2激酶在氯胺酮快速抗抑郁作用中的作用。
Adv Pharmacol. 2020;89:79-99. doi: 10.1016/bs.apha.2020.04.005. Epub 2020 May 22.
5
Neurobiological biomarkers of response to ketamine.氯胺酮反应的神经生物学生物标志物。
Adv Pharmacol. 2020;89:195-235. doi: 10.1016/bs.apha.2020.05.003. Epub 2020 Jun 18.
6
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.靶向稳态突触可塑性治疗心境障碍。
Neuron. 2020 Jun 3;106(5):715-726. doi: 10.1016/j.neuron.2020.05.015.
7
A New Paradigm for Achieving a Rapid Antidepressant Response.实现快速抗抑郁反应的新模式。
Drugs. 2020 Jun;80(8):755-764. doi: 10.1007/s40265-020-01303-1.
8
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.在一项针对难治性重度抑郁症的随机、安慰剂对照、交叉试验中，氯胺酮代谢物、临床反应和γ波功率
Neuropsychopharmacology. 2020 Jul;45(8):1398-1404. doi: 10.1038/s41386-020-0663-6. Epub 2020 Apr 6.
9
Psychedelic Psychiatry's Brave New World.迷幻精神病学的勇敢新世界。
Cell. 2020 Apr 2;181(1):24-28. doi: 10.1016/j.cell.2020.03.020.
10
A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression.一种 N-甲基-D-天冬氨酸受体甘氨酸位点拮抗剂前药 4-氯犬尿氨酸在治疗抵抗性抑郁症中的随机试验。
Int J Neuropsychopharmacol. 2020 Jul 29;23(7):417-425. doi: 10.1093/ijnp/pyaa025.
Zotero 插件